Reduction of salivary flow with transdermal scopolamine: A four-year experience

Y. P. Talmi*, Y. Finkelstein, Y. Zohar

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Scopoderm transdermal therapeutic system (TTS) is applied to prevent nausea and vomiting associated with motion sickness. Dry mouth is the most common side effect, appearing in up to two thirds of the patients treated. We have used this side effect to the benefit of patients with sialorrhea or with difficulties swallowing normally secreted amounts of saliva. More than 100 patients with tumors of the aerodigestive tract before and after surgery, and patients after parotidectomies, after tracheotomies, with peritonsillar abscesses, tonsillitis and pharyngitis, and neurologic disorders were thus treated. Reduced secretion of saliva was seen in 50% to 100% of the treatment groups. Other side effects were minimal and we recommend the use of scopoderm TTS for reduction of salivary flow.

Original languageEnglish
Pages (from-to)615-618
Number of pages4
JournalOtolaryngology - Head and Neck Surgery
Volume103
Issue number4
DOIs
StatePublished - 1990
Externally publishedYes

Fingerprint

Dive into the research topics of 'Reduction of salivary flow with transdermal scopolamine: A four-year experience'. Together they form a unique fingerprint.

Cite this